Abraxis BioScience (ABII)

MANAGEMENT

The following sets forth certain information with respect to our executive officers (other than Dr. Soon-Shiong and Mr. Moulder):

Mary Lynne Hedley, Ph.D. has served as our executive vice president of operations and chief scientific officer since July 2009. Prior to joining us, Dr. Hedley served as executive vice president of Eisai Corporation of North America following Eisai’s acquisition in 2008 of MGI PHARMA, INC. where she had served as executive vice president and chief scientific officer since 2005. She joined MGI PHARMA in 2004 as senior vice president and general manager. Previously, Dr. Hedley co-founded ZYCOS, Inc., a biotechnology company, and held roles of progressively greater responsibility ultimately leading to her serving as the company’s president and chief executive officer. Dr. Hedley’s early research career consisted of two consecutive postdoctoral fellowships at Harvard University from 1989 through 1996. She earned her bachelor of science degree in microbiology from Purdue University and her doctorate degree in Immunology from the University of Texas, Southwestern Medical Center.

Richard Rodgers has served as our senior vice president, finance, and administration since June 2009 and as our chief financial officer since July 2009. Mr. Rodgers most recently was senior vice president, controller and chief accounting officer of MGI PHARMA until the company’s acquisition by Eisai Corporation in 2008. In 2003, Mr. Rodgers was Corporate Controller of MedSource Technologies and from 1997 to 2002, he held various management positions at ADC Telecommunications Inc. Prior to that, he held finance and accounting positions at several private and public companies. Mr. Rodgers began his financial career in accounting at Arthur Anderson & Co. Mr. Rodgers earned his bachelor of science degree in Financial Accounting from St. Cloud State University, Minn., and his master of business administration degree in Finance from the University of Minnesota, Carlson School of Business.

Bruce Wendel has served as our executive vice president of corporate operations and development since the separation in November 2007. Mr. Wendel previously served as executive vice president of corporate development at Old Abraxis from March 2006 to the date of the separation. Mr. Wendel joined APP in 2004 as vice president of corporate development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development. Before joining APP, he served as vice president, business development & licensing for IVAX Corporation. Previously, Mr. Wendel served in the legal departments of Playtex and Combe. He earned a juris doctorate degree from Georgetown University Law School where he was an editor of Law & Policy in International Business, and a B.S. from Cornell University.

11

MANAGEMENT

The following sets forth certain information with respect to our executive officers (other than Dr. Soon-Shiong):

David O’Toole has served as our executive vice president and chief financial officer since June 2008. Prior to joining us, Mr. O’Toole served as a partner in the strategic client group with Deloitte & Touche LLP where he provided financial, consulting and international tax services to global companies, with particular expertise in the life sciences industry. From 1984 to 1989, Mr. O’Toole was with Arthur Andersen & Co., last serving as international tax manager. He is a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants, the California Healthcare Institute and the Southern California Biomedical Counsel. Mr. O’Toole earned his Bachelor of Science degree in accounting from the University of Arizona.

Bruce Wendel has served as our executive vice president of corporate operations and development since the separation in November 2007. Mr. Wendel previously served as executive vice president of corporate development at Old Abraxis from March 2006 to the date of the separation. Mr. Wendel joined APP in 2004 as vice president of corporate development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development. Before joining APP, he served as vice president, business development & licensing for IVAX Corporation. Previously, Mr. Wendel served in the legal departments of Playtex and Combe. He earned a Juris Doctorate degree from Georgetown University Law School where he was an editor of Law & Policy in International Business, and a B.S. from Cornell University.